Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares traded -1.51% lower at $118.97 on Wall Street last session.
In accordance with the data, 27 analysts cover Neurocrine Biosciences Inc. (NASDAQ:NBIX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $151.14 and a low of $101.00, we find $131.00. Given the previous closing price of $120.80, this indicates a potential upside of 8.44 percent. NBIX stock price is now 6.21% away from the 50-day moving average and 20.42% away from the 200-day moving average. The market capitalization of the company currently stands at $10.95B.
It has been rated a hold by 11 analysts and a buy by 12. Brokers who have rated the stock have averaged $129.21 as their price target over the next twelve months.
With the price target reduced from $140 to $130, Evercore ISI Downgraded its rating from Outperform to In-line for Neurocrine Biosciences Inc. (NASDAQ: NBIX). On October 11, 2022, UBS recently initiated its ‘Buy’ rating on the stock quoting a target price of $136, while ‘Wells Fargo’ rates the stock as ‘Equal Weight’.
In other news, BENEVICH ERIC, Chief Commercial Officer sold 100 shares of the company’s stock on Nov 10. The stock was sold for $12,536 at an average price of $125.36. Upon completion of the transaction, the Chief Commercial Officer now directly owns 15,643 shares in the company, valued at $1.86 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 08, Chief Commercial Officer BENEVICH ERIC sold 24,593 shares of the business’s stock. A total of $3,082,319 was realized by selling the stock at an average price of $125.33. This leaves the insider owning 15,643 shares of the company worth $1.86 million. Insiders disposed of 223,777 shares of company stock worth roughly $26.62 million over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NBIX stock. A new stake in Neurocrine Biosciences Inc. shares was purchased by T. ROWE PRICE INVESTMENT MANAGEMENT, INC. during the first quarter worth $119,961,000. LOS ANGELES CAPITAL MANAGEMENT LLC invested $94,220,000 in shares of NBIX during the first quarter. In the first quarter, CITADEL ADVISORS LLC acquired a new stake in Neurocrine Biosciences Inc. valued at approximately $28,035,000. TRI LOCUM PARTNERS LP acquired a new stake in NBIX for approximately $23,365,000. IMPAX ASSET MANAGEMENT GROUP PLC purchased a new stake in NBIX valued at around $17,846,000 in the second quarter. In total, there are 682 active investors with 96.70% ownership of the company’s stock.
Neurocrine Biosciences Inc. (NASDAQ: NBIX) opened at $121.13 on Wednesday. During the past 12 months, Neurocrine Biosciences Inc. has had a low of $71.88 and a high of $125.99. As of last week, the company has a debt-to-equity ratio of 0.11, a current ratio of 2.50, and a quick ratio of 2.40. The fifty day moving average price for NBIX is $112.30 and a two-hundred day moving average price translates $98.99 for the stock.
The latest earnings results from Neurocrine Biosciences Inc. (NASDAQ: NBIX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.18, missing analysts’ expectations of $0.6 by -0.78. This compares to $0.23 EPS in the same period last year. The net profit margin was 4.20% and return on equity was 4.10% for NBIX. The company reported revenue of $387.9 million for the quarter, compared to $296.0 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 31.05 percent. For the current quarter, analysts expect NBIX to generate $376.5M in revenue.
Neurocrine Biosciences Inc.(NBIX) Company Profile
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company’s portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company’s commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson’s disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company’s products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.